Clinical Evidence For HAI Therapy For Colorectal Cancer Liver Metastases
Mashaal Dhir MD, Heather L. Jones MPA-C, Yongli Shuai MS, Amber K. Clifford MPA-C, Samantha Perkins MPA-C, Jennifer Steve BS, Melissa E. Hogg MD, M. Haroon A. Choudry MD, James F. Pingpank MD, Matthew P. Holtzman MD, Herbert J. Zeh III MD, Nathan Bahary MD, PhD, David L. Bartlett MD & Amer H. Zureikat MD
In a study at University of Pittsburgh Medical Center, patients with unresectable liver metastases who received HAI therapy with the the Intera 3000 HAI Pump with floxuridine and systemic chemotherapy had a median overall survival rate of 32.8 months. Patients treated with systemic chemotherapy alone had a median survival of 15.3 months. Hepatic Artery Infusion as 2nd line doubled survival in unresectable CRLM, whether or not conversion was achieved.
Linda M. Pak MD, Nancy E. Kemeny MD, Marinela Capanu PhD, Joanne F. Chou MPH, Taryn Boucher BA, Andrea Cercek MD, Vinod P. Balachandran MD, T. Peter Kingham MD, Peter J. Allen MD, Ronald P. DeMatteo MD, William R. Jarnagin MD, Michael I. D'Angelica MD
Nancy Kemeny, M.D., Ying Huang, Ph.D., Alfred M. Cohen, M.D., Weiji Shi, M.S., John A. Conti, M.D., Murray F. Brennan, M.D., Joseph R. Bertino, M.D., Alan D.M. Turnbull, M.D., Deidre Sullivan, B.A., Jennifer Stockman, B.A., Leslie H. Blumgart, M.D., and Yuman Fong, M.D.
This RCT demonstrated that HAI as an adjuvant therapy after liver resection for CRLM resulted in significantly improved survival and hepatic progression free survival at 2 years.
Bas Groot Koerkamp, Eran Sadot, Nancy E. Kemeny, Mithat Gönen, Julie N. Leal, Peter J. Allen, Andrea Cercek, Ronald P. DeMatteo, T. Peter Kingham, William R. Jarnagin, and Michael I.